Danger Richard, Chesneau Mélanie, Paul Chloé, Guérif Pierrick, Durand Maxim, Newell Kenneth A, Kanaparthi Sai, Turka Laurence A, Soulillou Jean-Paul, Houlgatte Rémi, Giral Magali, Ramstein Gérard, Brouard Sophie
Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Department of Surgery, Emory University, Atlanta, Georgia, USA.
Kidney Int. 2017 Jun;91(6):1473-1481. doi: 10.1016/j.kint.2016.12.020. Epub 2017 Feb 24.
New challenges in renal transplantation include using biological information to devise a useful clinical test for discerning high- and low-risk patients for individual therapy and ascertaining the best combination and appropriate dosages of drugs. Based on a 20-gene signature from a microarray meta-analysis performed on 46 operationally tolerant patients and 266 renal transplant recipients with stable function, we applied the sparse Bolasso methodology to identify a minimal and robust combination of six genes and two demographic parameters associated with operational tolerance. This composite score of operational tolerance discriminated operationally tolerant patients with an area under the curve of 0.97 (95% confidence interval 0.94-1.00). The score was not influenced by immunosuppressive treatment, center of origin, donor type, or post-transplant lymphoproliferative disorder history of the patients. This composite score of operational tolerance was significantly associated with both de novo anti-HLA antibodies and tolerance loss. It was validated by quantitative polymerase chain reaction using independent samples and demonstrated specificity toward a model of tolerance induction. Thus, our score would allow clinicians to improve follow-up of patients, paving the way for individual therapy.
肾移植的新挑战包括利用生物信息设计一种有用的临床试验,以辨别个体治疗的高风险和低风险患者,并确定药物的最佳组合和合适剂量。基于对46例手术耐受患者和266例功能稳定的肾移植受者进行的微阵列荟萃分析得出的20个基因特征,我们应用稀疏Bolasso方法来识别与手术耐受相关的六个基因和两个人口统计学参数的最小且稳健的组合。这种手术耐受综合评分对手术耐受患者的鉴别能力的曲线下面积为0.97(95%置信区间0.94 - 1.00)。该评分不受免疫抑制治疗、起源中心、供体类型或患者移植后淋巴细胞增生性疾病史的影响。这种手术耐受综合评分与新发抗HLA抗体和耐受丧失均显著相关。它通过使用独立样本的定量聚合酶链反应得到验证,并对耐受诱导模型表现出特异性。因此,我们的评分将使临床医生能够改善对患者的随访,为个体化治疗铺平道路。